ACSL5, Dlat, Pdhb, G6pc, Mdh2, Cs, and other key enzymes in metabolic pathways regulated by ML may be the core targets of ML treatment for T2D. This evidence concerns the gene ACSL5 and type 2 diabetes mellitus.